Business Model Breakdown
How KALA BIO Inc Makes Money
KALA
Market Cap
$40M
Profit Margin
-1383.5%
Employees
38
The Short Version
KALA BIO Inc. was a clinical-stage biopharmaceutical company that aimed to develop treatments for rare and severe eye diseases. Its primary approach involved advancing pipeline candidates, such as KPI-012, through various phases of clinical trials, with the ultimate goal of gaining regulatory approval and commercializing these drugs. As a pre-revenue company, its business model relied heavily on successful drug development and subsequent market entry to generate revenue, funded by capital raises.
Where the Revenue Comes From
None (currently pre-revenue, as of Q1 2026 earnings)
Who buys: Historically targeted patients with rare ocular diseases; now effectively in search of a new market and customer base via a new pipeline.
Why It Works (Competitive Advantages)
- ✔None (Existing IP around failed assets is severely devalued; no clear new competitive advantage).
Economic Moat: None
What Our Analysis Says
DVR Score as of May 27, 2026
The dramatic reduction in score from 2.5/10 (25/100) to 0.5/10 (5/100) is directly attributable to several material negative events announced since the last analysis on 2026-03-26. KALA BIO suspended development of its primary pipeline asset, KPI-012, after it failed to meet primary and key secondary endpoints in its Phase 2b trial. This catastrophic pipeline failure nullifies the basis for the previous '10x growth potential contingent on successful clinical trials.' Furthermore, the company enacted a ~51% workforce reduction, implemented a 1-for-50 reverse stock split (a significant sign of distress), and experienced an 80% decline in market capitalization from $0.20B to $0.04B. These events fundamentally alter the company's prospects, moving it from a speculative growth play to a company in severe distress with limited near-term or medium-term pathways to value creation.